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Objective: To determine the effects of oxygen fluctuations on pigment epithelial-derived factor (PEDF) and vascular
endothelial growth factor (VEGF)/PEDF ratios in a relevant rat model of retinopathy of prematurity (ROP).
Methods: The expression of retinal PEDF mRNA and of VEGF and PEDF protein were determined using real-time
polymerase chain reaction or enzyme-linked immunosorbent assays at different postnatal day ages for rat pups raised in
room air (RA) or in a rat model mimicking ROP. Statistical outcomes were determined with factorial analyses of variance.
Mean VEGF and PEDF protein levels were determined at different ages for rats in the ROP model and for RA-raised rats,
and the ratio of VEGF/PEDF protein versus age was plotted. At postnatal day (P) 14, inner retinal plexus vascularization
had extended to the ora serrata in pups raised in RA. In the ROP model, avascular retina persisted at P14 and intravitreous
neovascularization developed at P18. Therefore, VEGF and PEDF expression was determined in the ROP model and in
RA-raised rat pups at P14 and P18.
Results: Older age was associated with increased PEDF mRNA (p<0.001), PEDF protein (p=0.005), and VEGF protein
(p=0.005), and VEGF protein (p<0.0001). Exposure to fluctuations of oxygen in the 50/10 oxygen-induced retinopathy
model compared to RA was associated with increased PEDF mRNA (p=0.0185), PEDF protein (p<0.0001), or VEGF
protein (p<0.0001). The VEGF/PEDF ratio favored angiogenic inhibition (<1.0) before but not on P14, when avascular
retina persisted in the ROP model but not in RA. The VEGF/PEDF ratio favored angiogenesis (>1.0) at P14 and P 18
when intravitreous neovascularization occurred in the ROP model.
Conclusions: Increased expression levels of VEGF and PEDF are associated with older postnatal day age or with exposure
to fluctuations in oxygen in the 50/10 oxygen-induced retinopathy model compared to RA. PEDF protein more closely
associates with avascular retinal features and neovascularization than does VEGF protein or the VEGF/PEDF in the ROP
model. Although PEDF has been proposed as a potential treatment in ROP, interventional studies using PEDF in an ROP
model to potentially reduce intravitreous neovascularization are  required  to  determine  timing,  efficacy,  and  dose of
Retinopathy of prematurity (ROP), first reported in 1941
[1],  reached  epidemic  status  over  the  following  decades,
blinding  many  preterm  infants.  At  that  time,  ROP  was
associated  with  high,  unregulated  oxygen  delivery  [2,3].
When  inspired  oxygen  levels  were  reduced,  ROP  was
virtually  eliminated.  Advances  in  neonatal  care  and
technology have since led to increased survival of very low
birthweight infants of young gestational age [4] and ROP has
re-emerged  [5].  High  oxygen  at  birth  is  now  avoided  in
countries that have implemented the technology to monitor
and regulate oxygen and thus may not be a cause of most cases
of ROP [6]. Rather, other factors have been associated with
severe ROP, including poor postnatal weight gain [7] and
oxygen stresses apart from high oxygen at birth, including
fluctuations in transcutaneous oxygen levels [8]. Investigators
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have suggested that lower inspired oxygen concentrations and
perhaps fewer fluctuations in oxygen are associated with the
reduced incidence of ROP [9]. However, a recent large-scale
prospective  clinical  trial  compared  85%–89%  oxygen
saturation to 91%–95% oxygen saturation and found the lower
oxygen  saturation  range  to  be  associated  with  a  reduced
incidence of ROP, but also with increased infant mortality
[10].  Therefore,  more  detailed  investigation  is  needed
regarding the effects of oxygen levels on severe ROP features
and retinal development in preterm infants. Such knowledge
would also aid in finding therapeutic agents for infant ROP.
Michaelson,  Ashton,  and  Patz  [2,3,11]  developed  a
hypothesis about how severe ROP occurred. It was believed
that high oxygen at birth led to avascular retinal areas that
became hypoxic when infants were weaned to room air (RA).
The  retinal  hypoxia  stimulated  the  production  of  an
angiogenic factor or factors [2,3,11]. Of numerous angiogenic
factors studied since the early hypothesis, vascular endothelial
growth factor (VEGF) has been recognized as one of the most
Molecular Vision 2011; 17:1577-1587 <http://www.molvis.org/molvis/v17/a176>
Received 8 November 2010 | Accepted 6 June 2011 | Published 10 June 2011
© 2011 Molecular Vision
1577
 PEDF.important  in  retinal  diseases  [12].  VEGF  is  increased  in
models of oxygen-induced retinopathy (OIR) with hypoxia-
induced  angiogenesis  following  high  constant  oxygen-
induced constriction [13] and in human ROP [14]. Excessive
signaling of VEGF through VEGF receptor 2 (VEGFR2) has
been  found  to  disrupt  developmental  angiogenesis  [15].
Conversely, inhibition of VEGF signaling through VEGFR2
has  reduced  pathologic  intravitreous  neovascularization
[16-20]  without  interfering  with  ongoing  retinal  vascular
development [16,18,19]. VEGF mRNA was detected in an
infant retina that had severe ROP [21], and infants operated
on for progressive stage 4 ROP had elevated ocular VEGF
protein compared to control infants undergoing congenital
cataract surgery [22]. Finally, intravitreous injections of anti-
VEGF agents have been reported to reduce vascularly active
features, such as intravitreous neovascularization in severe
ROP  [23].  However,  later  retinal  detachment  has  been
reported in some infants treated with anti-VEGF agents [24]
Concerns also exist about using anti-VEGF agents in preterm
infants  because  VEGF  is  involved  in  angiogenesis  and
neuroprotection,  both  important  in  developing  preterm
infants. Therefore, other treatments must be considered.
One such treatment is pigment epithelial-derived factor
(PEDF),  which  is  a  potent  angiogenic  inhibitor  [25].
Exogenous  administration  of  PEDF  decreased
neovascularization  in  OIR  models  of  hypoxia-induced
angiogenesis  following  high  constant  oxygen-induced
capillary constriction [26,27] or in models of laser-induced
injury [28]. In some studies, decreased levels of PEDF have
been associated with proliferative diabetic retinopathy and
age-related macular degeneration (AMD) [29,30], whereas
increased  levels  have  been  shown  to  reduce  morbidity  in
neovascular  AMD  [31].  PEDF  is  believed  to  regulate
angiogenesis  through  multiple  mechanisms,  including
downregulation of VEGF expression [32]. A ratio of VEGF/
PEDF  of  less  than  1.0  has  been  associated  with  reduced
angiogenesis in some models of OIR [33-35]. However, these
models may not reflect the severe ROP that occurs in infants
in neonatal units that monitor and regulate oxygen for preterm
infants.  We  became  interested  in  PEDF  as  a  potential
treatment in ROP because it is neuroprotective [25] and anti-
inflammatory [36], potentially may regulate VEGF-induced
pathologic angiogenesis, and has been safely tolerated in a
human clinical trial [31].
Much  of  what  has  been  learned  about  proposed
mechanisms in ROP has been discovered using models of high
oxygen to induce capillary constriction followed by relative
hypoxia-induced angiogenesis [34,37,38]. These models of
OIR  with  hypoxia-induced  angiogenesis  following  high
constant  oxygen  [13]  may  be  relevant  to  human  ROP
described  in  the  1940s  that  was  associated  with  high
unregulated oxygen [39]. We use a model developed by John
Penn [40], in which Sprague-Dawley pups and their dams are
placed  into  a  controlled  environment  where  the  oxygen
fluctuates between 50% and 10%. The model uses oxygen
levels relevant to ROP in that it yields rat arterial oxygen
concentrations  similar  to  transcutaneous  oxygen  levels
reported in infants with severe ROP [40]. The model also
produces  a  characteristic  appearance  of  severe  ROP  with
peripheral avascular retina similar to zone II ROP [40,41],
followed by retinal tortuosity similar to plus disease [42], and
then  intravitreous  neovascularization  at  the  junctions  of
vascular and avascular retina, similar to stage 3 ROP [41,43].
The model uses fluctuations in oxygen, a risk factor for severe
ROP [8]. Further, abnormalities in photoreceptor and post-
receptor responses in electroretinograms of pups exposed to
this  model  share  similarities  with  those  found  in  human
preterm infants with severe ROP [44]. For these reasons, the
Penn 50/10 model is described as the ROP model [42]. We
and others have used this model to study the effects of oxygen
and other stresses on the development of severe ROP features
[18,19] and the relationships between features and angiogenic
growth factor signaling pathways [45-49]. In this study, as a
first, step to determine whether PEDF might be a therapeutic
agent to safely prevent severe ROP, we sought to determine
the effect of relevant oxygen levels on the regulation of VEGF
and PEDF in association with severe ROP features using the
Penn rat model of ROP.
METHODS
ROP  model:  All  animal  studies  were  approved  by  the
University  of  North  Carolina’s  Institute  for  Laboratory
Animal Research (Guide for the Care and Use of Laboratory
Animals) and the University of Utah’s Institute of Animal
Care  and  Use  Committee,  and  complied  with  the  ARVO
Statement for the Use of Animals in Ophthalmic and Visual
Research. Within 4 h of birth at postnatal day (P) 0, litters of
16  newborn  Sprague-Dawley  rat  pups  with  their  dams
(Charles  River,  Wilmington,  MA)  were  placed  in  an
Oxycycler incubator (Biospherix, New York, NY) to cycle
inspired oxygen between 50% oxygen and 10% oxygen every
24 h. Pups from other litters were used to supplement deficient
litters. To maintain the reproducibility of the ROP model,
litters were never depleted below 12 pups. Often, this required
that  whole  litters  be  used  for  individual  postnatal  day
measurements. After seven cycles of oxygen fluctuations at
P14, pups were then placed into RA for 4 days [40]. Oxygen
levels  were  monitored  daily  and  recalibrated  as  needed.
Carbon dioxide in the cage was also monitored daily and was
flushed from the system by maintaining sufficient gas flow
and by adding soda lime, if needed.
We analyzed retinas from pups of several postnatal day
ages preceding and including P14 when full vascularization
of the inner retinal plexus occurred in RA-raised pups, but
persistent avascular retina was present in the ROP model. We
also  analyzed  pups  at  P18  when  intravitreous
neovascularization occurred in the ROP model. Postnatal day
0 was analyzed as the baseline value. In the ROP model, P8,
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session  (10%  inspired  O2)  and  P11  and  P13  following  a
hyperoxic session (50% inspired O2). Following P14, pups
were placed into an RA environment (21% FiO2).
Dissection of retinal tissue for mRNA and protein analyses:
Animals  were  euthanized  with  pentobarbital  (80  mg/kg
intraperitoneal injection) at the beginning of the change in
inspired  oxygen  level.  Eyes  were  placed  into  phosphate
buffered saline (PBS) after the hyaloid vessels and remaining
vitreous  were  removed.  For  fresh  tissue,  retinas  were
dissected without ora serratas. The retina was removed from
the eyecup and frozen in modified radioimmunoprecipitation
assay (RIPA) buffer (20 mM Tris base, 120 mM NaCl, 1%
Triton  X-100,  0.5%  sodium  deoxycholate,  0.1%  sodium
dodecyl sulfate (SDS), and 10% glycerol) with a protease
inhibitor cocktail (1:100; Sigma, St. Louis, MO) and 1 M
orthovanadate  (1:100;  Sigma),  then  stored  at  −80  °C  for
protein or in RNA later (Applied Biosystems, Carlsbad, CA)
for RNA until analysis.
Dissection of retinal tissue for retinal flat mounts: For flat
mounts,  following  enucleation,  eyes  were  fixed  in  2%
paraformaldehyde for 2 h. Retinas were isolated as described
previously [50], but with ora serratas intact, and placed into
PBS after the hyaloid vessels and remaining vitreous were
removed.  By  making  four  incisions  90  degrees  apart,  the
retinas were flattened and then placed onto microscope slides.
Tissue  staining  and  analysis  of  flat  mounts:  To  stain  the
vasculature, the flattened retinas were first permeabilized in
ice-cold 70% v/v ethanol for 20 min, then in PBS/1% Triton
X-100 for 30 min, and then incubated with Alexa Fluor 568
conjugated G. simplicifolia (Bandeiraea) isolectin B4 (5 μg/
ml; Molecular Probes, Carlsbad, CA) in PBS overnight at
4 °C, as previously described [18]. Images of the retinal blood
vessels were captured using a Nikon 80i Research Upright
Microscope, Melville, NY with Surveyor/Turboscan software
and digitally stored for analysis.
Real time quantitative PCR: Total RNA was extracted using
the RNAeasy Mini Kit (Qiagen, Valencia CA). Assays were
performed using the Applied Biosystems 7500 Real-Time
PCR  System.  Briefly,  1  μg  of  total  RNA  was  reverse-
transcribed  into  cDNA  using  a  High  Capacity  cDNA  Kit
(Applied  Biosystems),  according  to  the  manufacturer’s
protocol. Each TaqMan reaction (16 μl) contained 20 ng of
cDNA,  8  μl  of  TaqMan  PCR  MasterMix  (Applied
Biosystems) and 1 μM forward primer, 1 μM reverse primer,
and 1 μM probe. Primers were specific for rat (annealing
temperature 60 °C) PEDF: forward 5′-CCA ACT CTT TGC
AGG ACA TG-3′, reverse 5′-TCA CAG GTT TGC CGG
TAA TC-3′, and probe 5′ -ACA GTC CTT GTT TGA GTC
CCC TGA C −3′. Primers and probes were made by UNCs
Oligonucleotide  Core  Facility.  Each  sample  was  run  in
duplicate, and each experiment included three non-template
control wells. The 7500 System Software calculates cycle
threshold (Ct) automatically for each well and each value was
normalized to rat β-actin (Actb). Rat Actb was chosen as the
control gene because its expression had previously been found
to be stable under various oxygen stresses. Primers for rat
Actb were forward 5′-TGC CTG ACG GTC AGG TCA-3‘,
reverse 5′-CAG GAA GGA AGG CTG GAA G-3‘, and probe
5′-CAC TAT CGG CAA TGA GCG GTT CCG-3‘. Postnatal
day age 0 indicated retinal tissue harvested within 4 h of birth
and was used in analysis for both the ROP and RA groups.
For graphical representation of PEDF mRNA, this value was
scaled to 1.0 and used as the standard against which fold
changes in mRNA expression were compared. However, for
statistical analysis, raw data were used as described below.
Protein analysis: Retinal samples, which were stored in RIPA
buffer at −80 °C, were thawed, homogenized, and centrifuged
(16,000× g, 10 min, 4 °C). Total protein was quantified with
a Bicinchoninic Acid (BCA) Protein Assay Kit (Bio-Rad,
Hercules,  CA,  modified  from  the  Lowry  assay)  [51].
Supernatants were assayed without dilution in duplicate using
commercially available ELISA kits, raised against rat VEGF
(R&D  Systems,  Rochester  MN)  or  human  PEDF
(BioProducts,  Middletown,  MD).  The  VEGF  ELISA
measures all VEGF splice variants, with the most prevalent
splice variant, VEGF164, representing the greatest percentage
of the ELISA value [52]. The mean minimum detectable dose
for  VEGF  was  6.4  pg/mL.  For  the  PEDF  ELISA,  the
manufacturer  estimates  a  10–50×  reduced  affinity  for  rat
PEDF; however, our results met criteria for test validity and
fell within the standard curve. To take into account potential
reduced affinity, we compared retinal values from rat pups in
the 50/10 OIR to rat pups in control RA taken at the same
postnatal day ages.
Calculation of VEGF/PEDF ratios: For each postnatal day
age, the mean values of VEGF or PEDF protein determined
for the ROP model were normalized to the respective mean
RA values of growth factors at the same postnatal day ages.
These normalized values were then used to form a VEGF to
PEDF ratio under the two conditions.
In situ hybridization: Whole eyes were fresh frozen in Optimal
Cutting Temperature (OCT) compound and stored at −80 °C.
Serial 14-µm-thick sections were cut for in situ hybridization,
which was performed at the University of North Carolina’s In
Situ Hybridization Core Facility. Mouse PEDF cDNA [53]
(1374  bp,  GenBank  AF017055)  was  kindly  supplied  by
Joshua  Barnett  (Vanderbilt  University,  Nashville,  TN).
PEDF cDNA was subcloned into the pBluescript SK vector
(Stratagene, La Jolla, CA) and linearized with HindIII and
XbaI  to  produce  templates  for  in  vitro  transcription  of
antisense  and  sense  riboprobes.  This  transcription  was
performed  using  a  DIG  RNA  Labeling  Kit  (Roche
Diagnostics, Indianapolis, IN) to produce a single stranded
digoxigenin-11-uridine-triphosphate-labeled  probe.
Hybridization with a sense strand riboprobe was performed
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probe was localized in tissue using an alkaline-phosphatase-
conjugated anti-digoxigenin antibody and visualized using
NBT/BCIP  solution  (Roche  Diagnostics,  Mannheim
Germany). PEDF in situ hybridization was imaged using an
Olympus DSU-IX81 spinning disc confocal microscope.
Immunostaining for PEDF: Immunostaining was done using
mouse  anti-PEDF  (Millipore,  Temecula  CA)  as  primary
antibody and visualized using Alexa-Fluor 588-conjugated
goat anti-mouse secondary antibodies (Invitrogen, Carlsbad
CA) using an Olympus (Tokyo, Japan) DSU-IX81 spinning
disc confocal microscope. No primary antibody was used in
the controls.
Statistical analysis: For each postnatal day age, at least five
retinas from different pups taken from at least two different
litters were analyzed. The mean fold changes relative to beta-
actin are graphically represented, with error bars representing
standard errors. While these normalized ratios were used for
graphical representation in the figures, to avoid bias, the raw
data were used for statistical analysis as described below.
Initially, Actb was analyzed by regression analysis of the
ratio of each Actb/VEGF splice variant or PEDF mRNA for
the Ct1 value against respective Actb/VEGF splice variants or
PEDF mRNA for the Ct2 value, and the slope was found to
be  indistinguishable  from  1.0,  the  ideal  value  [54].  The
geometric means of the product of the two ratios were then
determined for each postnatal day age and treatment, and this
was the outcome analyzed. For the analysis of VEGF and
PEDF protein by ELISA, the protein concentration was the
outcome analyzed. A factorial ANOVA with a completely
randomized treatment arrangement was used to determine the
significance of the factors, postnatal day age, and treatment
(RA  versus  50/10  OIR  model).  Post-hoc  testing  of  the
treatment  and  increasing  postnatal  day  age  by  treatment
interaction means was accomplished using protected t-tests on
least-squares means, with alpha level adjustment for multiple
comparisons among means accomplished using a method of
simulation [55].
RESULTS
ROP model: Figure 1 shows representative flat mounts of
retinas from an RA-raised pup at P14 (Figure 1C),  and   from
pups in the ROP model at P14 (Figure 1A) and  P18 (Figure
1B). In the ROP  l e d o m    at  P14,  avascular  retina comprised
32.8±10.6% of the total retinal area, whereas in RA pups, there
was no avascular retina present [52]. At P18, avascular retina
comprised 23.1±6.2% of the total retina and intravitreous
neovascularization was present in approximately eight clock
hours  of  all  retinas  in  the  ROP  model  [52],  making  up
2.29±0.68% of the total retinal area. Numbers are mean±SEM.
PEDF tissue localization: To determine the localization of
PEDF mRNA within the retina of the ROP model, we first
performed in situ hybridization on P14 retinal sections from
pups in the ROP model. At this postnatal day age, retinal
vascularization is restricted to 70%–75% of the retina in the
ROP model [52], as shown in Figure 1. PEDF mRNA was
detected in ganglion cells and cells throughout the inner and
outer nuclear layers (Figure 2). Sense labeled sections of P14
ROP retinas were blank (Figure 2).
We then localized PEDF protein in retinal cryosections
of P14 pups in the ROP model and found labeling in inner and
outer plexiform layers and in the inner nuclear layer. A lower
level of PEDF immunostaining was also seen in the outer
nuclear  layer  (Figure  2E).  Figure  2F  shows  nonspecific
staining of the secondary antibody.
PEDF mRNA quantification: To quantify the expression of
PEDF mRNA, real time PCR was performed on retinal lysates
of RA-raised pups and those in the ROP model at postnatal
day ages between P0 and P18. The relative PEDF mRNA level
was similar for the P0 and P8 time points and increased from
Figure 1. Retinal flat mounts at P14 and P18 in the ROP model and at P18 in RA samples. Representative lectin-stained flat mounts from rat
pups in the ROP model or RA conditions. In the ROP model, avascular retina remains at P14 (A), while in RA, intraretinal vascularization is
complete at P14 (C). In the ROP model, after seven cycles of oxygen fluctuations by P14, pups are then moved into RA for 4 days. At P18,
intravitreous neovascularization occurs at the junction of vascularized and avascular retina (B).
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retinal  PEDF  expression  was  higher  compared  to  RA
counterparts at most time points and appeared to be expressed
to a greater extent than in RA pups at earlier postnatal day
ages.  Within  the  model,  the  pattern  of  PEDF  mRNA
expression  level  fluctuated  in  association  with  oxygen
concentration  in  the  ROP  model.  It  tended  to  increase
following hyperoxia at P11 and P13 and decrease following
hypoxia at P8, P12, and P14. Based on statistical analysis,
increased  fold  expression  of  PEDF  was  significantly
associated with older postnatal day age (ANOVA, p=0.0001)
or  with  the  ROP  model  compared  to  RA  (ANOVA,
p=0.0185).  Post-hoc  testing  revealed  only  a  significantly
increased fold expression in PEDF mRNA at P11 in the ROP
model compared to the RA group (p=0.0017).
PEDF protein concentration in RA and ROP models: PEDF
protein was measured in retinal lysates taken at the same
postnatal day ages as mRNA from rats raised in RA or exposed
to  the  ROP  model.  PEDF  protein  increased  with  older
postnatal day age in retinas from RA-raised rats (Figure 4).
For rats in the ROP model compared to those raised in RA,
the  pattern  of  PEDF  increased  before  and  on  P14  when
avascular retina persisted in the ROP model, but not in RA
samples.  However,  at  P18  when  neovascularization  was
present in the ROP model, the protein levels of PEDF and RA
samples were similar. Compared to that with PEDF mRNA,
the pattern of PEDF protein concentration was less closely
associated with changes in oxygen concentration in the model.
Statistical analysis revealed increased PEDF in association
with older developmental age (ANOVA, p=0.005) or with
exposure  to  the  ROP  model  compared  to  RA  samples
Figure 2. Tissue labeling of PEDF mRNA and protein in rat ROP model at P14. Sections of P14 rat retina in ROP model labeled by in situ
hybridization for PEDF mRNA showing message in the ganglion cell layer (GCL), and in the inner and outer nuclear layers (INL, ONL; A,
C). Control using sense probe showed no signal (B, D). Immunostaining for PEDF protein in P14 ROP model showed labeling in the inner
and outer plexiform layers and inner and outer nuclear layers (E). No primary control showed nonspecific staining in the ganglion cell layer
(F). Magnification calibration bars are 100 µm (A, B) and 50 µm (C-F).
Figure  3.  Quantification  of  PEDF
mRNA  in  ROP  model  at  different
postnatal  day  ages.  Real  time
polymerase  chain  reaction  values  for
PEDF  expression  in  the  retina  of  rat
pups from selected postnatal days (P) 0
through P18 in RA or the ROP model.
Increased PEDF expression associated
with  older  developmental  age
(p=0.0001)  or  with  the  ROP  model
compared to RA (ANOVA, p=0.0185).
*Post-hoc  testing  revealed  increased
PEDF mRNA at P11 in the ROP model
compared to RA samples (p=0.0017).
Error  bars  represent  standard  errors.
Each time point had at least five retinas
from different pups taken from at least
two  different  litters.  mRNA  indicates
mRNA.
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significantly increased in the ROP model compared to RA
samples at P11 and P13, each following a 24 h exposure to
hyperoxia (p=0.0041, p=0.0022, respectively).
VEGF protein concentration in RA samples and in the ROP
model:  According  to  previously  published  studies,  the
VEGF164 isoform is the most prevalent during RA retinal
development and in the ROP model [52,56]. It was also shown
that VEGF mRNA and protein increased with older postnatal
day age and in the ROP model [56]. In agreement with this,
VEGF  protein  (Figure  5)  was  significantly  increased  in
association with older postnatal day age (ANOVA, p<0.0001)
or with exposure to the ROP model compared to RA samples
(ANOVA, p<0.0001). Based on post-hoc testing, there were
significant  increases  in  VEGF  protein  in  the  ROP  model
compared to RA samples at P8, P12, P14, and P18 (p=0.0002,
p<0.0001, p<0.0001, p=0.0117). In the ROP model, VEGF
was  significantly  greater  following  hypoxic  compared  to
hyperoxic cycles (P12 versus P11 [p=0.0014], P12 versus
P13, and P14 versus P13; p<0.0001, each).
VEGF/PEDF ratios: To compare VEGF and PEDF, we first
developed ratios of the ROP to RA mean retinal protein values
Figure  4.  Quantification  of  PEDF
protein  in  ROP  model  at  different
postnatal  day  ages.  ELISA
measurements of retinal PEDF protein
from  selected  postnatal  days  (P)  0
through P18 in RA or in the ROP model.
Increased PEDF associated with older
developmental  age  (p=0.005)  or  the
ROP model compared to RA samples
(ANOVA, p<0.0001). *Post-hoc testing
revealed increased PEDF in the ROP
model compared to RA at P11 and P13
(p=0.0041,  p=0.0022  respectively).
Error  bars  represent  standard  errors.
Each time point had at least five retinas
from different pups taken from at least
two different litters.
Figure  5.  Quantification  of  VEGF
protein  in  ROP  model  at  different
postnatal  day  ages.  ELISA
measurements of retinal VEGF protein
from postnatal days (P) 0 through P18 in
RA or the ROP model. Increased VEGF
associated  with  older  developmental
age (ANOVA, p<0.0001) or the ROP
model  compared  to  RA  samples
(ANOVA, p<0.0001). Post-hoc testing
revealed increased VEGF protein in the
ROP model compared to RA at P8, P12,
P14,  and  P18  (p=0.0002,  p<.0001,
p<0.0001,  p=0.0117).  In  the  ROP
model, VEGF was significantly greater
following  hypoxic  compared  to
hyperoxic  cycles  (P12  versus  P11
[p=0.0014], P12 versus P13, and P14
versus P13; p<0.0001, each). Error bars
represent  standard  errors.  Each
postnatal day age had at least five retinas
from different pups taken from at least
two different litters.
Molecular Vision 2011; 17:1577-1587 <http://www.molvis.org/molvis/v17/a176> © 2011 Molecular Vision
1582for VEGF and PEDF at each postnatal day age tested. We then
created a ratio between VEGF and PEDF at each postnatal day
age  and  graphically  represented  these  (Figure  6).  This  is
similar to methods used in previous reports [35]. At P14,
retinal vascularization of the inner plexus is complete in RA
controls, whereas avascular retina persists in the ROP model
[52]  (Figure  1). At  P11  and   P13,  the  VEGF/PEDF  ratio
favored angiogenic inhibition (ratio less than 1.0). However,
at P14, the VEGF/PEDF protein ratio favored angiogenic
stimulation (greater than 1.0). The ratios were approximately
3.0 at P14 and P18 in the ROP model.
DISCUSSION
Normal development of the retinal vasculature depends on the
integration of several signaling events influenced by a delicate
balance  of  angiogenic  agonists  and  inhibitors.  Of  many
factors, two important ones in retinal development are VEGF
[57,58]  and  PEDF  [59].  VEGF  is  an  angiogenic  agonist,
upregulated in hypoxia [60], whereas PEDF is an angiogenic
antagonist, upregulated by hyperoxia [59]. Using a model of
ROP, we studied the effects of oxygen stresses, relevant to
preterm  infants  with  ROP,  on  PEDF  expression  and  the
relative differences in the VEGF/PEDF ratio in comparison
to control rat pups raised in RA. Compared to RA, we found
that retinal PEDF was increased in association with avascular
retina in the ROP model.
The interaction of VEGF and PEDF has been explored in
other  models.  Oxidative  stress  increased  the  angiogenic
potential  of  cultured  RPE  cells  in  association  with  an
increased fold expression of VEGF to PEDF [33]. Using a
model of high oxygen-induced retinopathy (OIR) in rats, the
fold expression of VEGF was reduced during hyperoxia but
increased  during  relative  hypoxia-induced  endothelial
proliferation [35]. Previously, using the ROP model, PEDF
was found to approach levels of that in RA samples at P18
[61],  and  the  VEGF/PEDF  ratio  favored  angiogenesis  in
association  with  the  development  of  intravitreous
neovascularization in the ROP model at P18. We had similar
findings  in  our  study.  However,  we  also  studied  younger
postnatal day ages before the development of intravitreous
neovascularization at P18. Earlier ages in the model may
relate to the preterm infant retina before the development of
severe ROP. We found that the pattern of the VEGF/PEDF
ratio of retina in the ROP model normalized to RA was similar
to  that  of  VEGF  protein,  favoring  angiogenic  stimulation
following a hypoxic cycle (10% O2) and favoring inhibition
following a hyperoxic cycle (50% O2). The VEGF/PEDF
ratio favored angiogenic inhibition before but not at P14,
when  avascular  retina  persisted  in  the  ROP  model  but
vascularization of the inner plexus was complete in RA pup
retinas. The VEGF/PEDF ratio, PEDF, and VEGF protein
favored  angiogenesis  at  P18  when  intravitreous
neovascularization  occurred.  The  PEDF  protein  level
appeared more closely associated with features of the ROP
model than did VEGF or the VEGF/PEDF ratio.
Most reports that studied young postnatal day ages in
models of OIR did not use relevant animal models such as the
Penn ROP model. Gao et al. [62] examined the effect of high
constant oxygen in rats and found that the ratio of VEGF/
PEDF  corresponded  to  the  degree  of  intravitreous
neovascularization. The investigators also found a difference
according to the strain of rat, in that Brown Norway rats had
more  severe  neovascularization  than  did  Sprague-Dawley
rats, suggesting a genetic component to oxygen sensitivity.
Based on a verbal communication, no differences in the extent
of intravitreous neovascularization were found between the
two rat strains subjected to oxygen fluctuations. However, it
is not clear what the extremes in inspired oxygen were.
PEDF might be considered as a therapy to prevent severe
ROP in human preterm infants, potentially as an intravitreal
Figure 6. Ratio of VEGF/PEDF protein
in ROP model normalized to RA values.
The ratio of mean VEGF/PEDF in the
ROP  model  normalized  to  respective
RA  means  at  selected  postnatal  day
ages. A ratio >1.0 favors angiogenesis
(P8, P12, P14, P18) and a ratio <1.0
favors angiogenic inhibition (P11 and
P13).
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1583injection  like  anti-VEGF  agents  currently  used  for  adults
[23].  The  reasons  to  consider  PEDF  are  that  it  inhibits
angiogenesis [27], in part by promoting apoptosis [26,63], it
mitigates  inflammation,  and  it  is  neuroprotective  [64].
Therefore,  it  would  potentially  be  safer  than  anti-VEGF
agents. In addition, it was reported that overexpression of
PEDF with an adenovirus associated vector was not shown to
adversely affect the radial expansion of retinal vessels in wild
type  mice  raised  in  RA,  suggesting  that  retinal  vascular
development  can  proceed  in  conditions  of  overexpressed
PEDF [65]. Additional evidence of potential protective effects
of PEDF was shown in PEDF−/− mice that were found to be
more  susceptible  to  hyperoxia-mediated  retinal  vascular
constriction  and  retraction  compared  to  PEDF+/+  mice
subjected to the same conditions. This occurred even though
retinal VEGF protein was increased in PEDF−/− compared to
PEDF+/+ [66]. These data suggest the presence of PEDF may
even benefit the development of intraretinal vascularization,
at least in the condition of high oxygen.
The findings in this manuscript are associations and are
not causative, and further study is warranted to address the
question of whether exogenous PEDF delivered early when
the  VEGF/PEDF  ratio  is  less  than  1.0  would  lead  to
persistence of the avascular retina, an unwanted outcome in
ROP. Our findings may be relevant to ROP currently because
the Penn ROP model more closely reflects oxygen levels and
the appearance of ROP in current neonatal units than earlier
models of OIR that were developed to mimic the ROP of the
1940s.
Changes in the patterns of PEDF concentrations based on
the exposure to hypoxia or hyperoxia were best appreciated
in fold expressions of mRNA, and less so in protein. As
anticipated [59], PEDF mRNA was upregulated following
periods of hyperoxia at P11 and P13. The PEDF antibody
recognizes human PEDF but is estimated by the manufacturer
to have a lower affinity for rat PEDF. For this reason, we
normalized  mean  values  of  PEDF  and  VEGF  protein  to
respective RA means. PEDF protein expression may also be
less  sensitive  to  fluctuating  oxygen  levels  than  mRNA
because of the time required for protein translation, post-
translational  modification,  and  possibly  sequestration  of
growth factors in extracellular matrix.
In summary, we found that compared to RA counterparts,
both VEGF and PEDF were significantly increased in the rat
ROP model at early and late postnatal day ages. However, we
found the relative expression level of VEGF to PEDF protein
favored angiogenic inhibition before but not at P14 when
avascular retina persisted in the model but vascularization of
the  inner  retinal  plexus  was  complete  in  RA.  Evidence
suggests that PEDF can be released in response to several
stresses and have beneficial effects as a neuroprotectant and
anti-inflammatory agent. Further study is needed to determine
the timing and type of delivery of PEDF in the ROP model.
In this study, the relative expression of PEDF protein was
more closely associated with early features in the ROP model,
i.e., avascular retina, than was the VEGF or the VEGF/PEDF
ratio.
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